Novo Nordisk shares dive after heart medicine fails trial, dealing another blow toits pipeline
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday. This story matters for Finance & Markets readers tracking largecap. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. LargecapNews curates and briefs the finance & markets stories that matter. Our editorial policy →